NanoView, Beth Israel Deaconess Medical Center Launch Immuno-Oncology Biomarker Study

NEW YORK – NanoView Biosciences said on Thursday that it has signed an agreement with Beth Israel Deaconess Medical Center to study biomarkers carried by exosomes in patients undergoing immune checkpoint inhibitor therapy (ICIT) for cancer.

NanoView, Beth Israel Deaconess Medical Center Launch Immuno-Oncology Biomarker Study